Trial Profile
Observational study of treatment of epidermal growth factor receptor activating mutation positive (EGFRm+) advanced or recurrent non-small-cell lung cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Apr 2013 New trial record